ArticleJournal of neuro-oncology2026
Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe examined associations of county- and tract-level Social Vulnerability Index (SVI) with survival and treatment-related outcomes in adults with IDH-wildtype glioblastoma (GBM) or IDH-mutant grade 4 astrocytoma.
methodsAdults treated at MD Anderson from 2020 to 2025 with PROACTIVE consent, survival follow-up, and Texas residential data were included. The 2022 CDC/ATSDR SVI was modeled per 0.1 increase (10 percentile points). Primary Cox models for GBM adjusted for age, sex, performance status, extent of resection, MGMT methylation, insurance, and distance. Proportional hazards were assessed using Grambsch-Therneau tests.
resultsCohorts included 398 patients with GBM and 62 with IDH-mutant grade 4 astrocytoma. In GBM, SVI was not associated with survival in county-level analyses (HR per 0.1 increase, 1.00; 95% CI, 0.96-1.05; P = 0.920) or Houston-area tract-level analyses (HR, 1.05; 95% CI, 0.98-1.13; P = 0.176). In exploratory time-varying analysis, the SVI-mortality association attenuated over follow-up (interaction P = 0.028). Higher tract-level SVI was associated with greater odds of not undergoing gross-total resection (OR, 1.19; 95% CI, 1.07-1.33; q = 0.010) and lower odds of clinical-trial treatment (OR, 0.81; 95% CI, 0.71-0.92; q = 0.008). No significant survival association was identified in exploratory astrocytoma analyses.
conclusionAmong patients who reached tertiary neuro-oncology care, primary Cox models did not identify a statistically significant association between SVI and survival. Higher tract-level SVI was associated with less extensive resection and lower odds of clinical-trial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.